

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	hours per response:
	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

<b>1. Name and Address of Reporting Person*</b> <u>Bitterman Kevin</u> <hr/> (Last) (First) (Middle) <u>C/O DISC MEDICINE, INC.</u> <u>321 ARSENAL STREET, SUITE 101</u> <hr/> (Street) <u>WATERTOWN MA 02472</u> <hr/> (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b> <u>Disc Medicine, Inc. [ IRON ]</u>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	<b>3. Date of Earliest Transaction (Month/Day/Year)</b> <u>10/15/2025</u>	
	<b>4. If Amendment, Date of Original Filed (Month/Day/Year)</b>	<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/15/2025		S		19,542	D	\$77.16 <sup>(1)</sup>	481,079	I	See footnote <sup>(2)</sup>
Common Stock	10/15/2025		S		2,618	D	\$77.76 <sup>(3)</sup>	478,461	I	See footnote <sup>(2)</sup>
Common Stock	10/16/2025		S		1,425	D	\$77.11 <sup>(4)</sup>	477,036	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		1,125	D	\$84.89	475,911	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		1,125	D	\$84.89	419,424	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		3,000	D	\$86.13 <sup>(6)</sup>	472,911	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		3,000	D	\$86.13 <sup>(6)</sup>	416,424	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		5,066	D	\$87.37 <sup>(7)</sup>	467,845	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		5,065	D	\$87.37 <sup>(7)</sup>	411,359	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		13,014	D	\$88.91 <sup>(8)</sup>	454,831	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		13,014	D	\$88.91 <sup>(8)</sup>	398,345	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		2,251	D	\$89.7 <sup>(9)</sup>	452,580	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		2,251	D	\$89.7 <sup>(9)</sup>	396,094	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		10,094	D	\$90.66 <sup>(10)</sup>	442,486	I	See footnote <sup>(2)</sup>
Common Stock	10/17/2025		S		10,095	D	\$90.66 <sup>(10)</sup>	385,999	I	See footnote <sup>(5)</sup>
Common Stock	10/17/2025		S		450	D	\$91.88 <sup>(11)</sup>	442,036	I	See footnote <sup>(2)</sup>

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/17/2025		S		450	D	\$91.88 <sup>(11)</sup>	385,549	I	See footnote <sup>(5)</sup>
Common Stock								51,000	I	See footnote <sup>(12)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Explanation of Responses:**

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.75 to \$77.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (6), (7), (8), (9), (10) and (11).
- These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$77.75 to \$77.77 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.52 to \$77.30 inclusive.
- These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$85.91 to \$86.90 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$87.12 to \$88.03 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$88.17 to \$89.04 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$89.25 to \$90.23 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$90.25 to \$91.24 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.37 to \$92.15 inclusive.
- These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.

/s/ Ommer Chohan, Attorney-in-Fact      10/17/2025

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**